These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33430656)

  • 1. Structural vaccinology of malaria transmission-blocking vaccines.
    Patel PN; Tolia N
    Expert Rev Vaccines; 2021 Feb; 20(2):199-214. PubMed ID: 33430656
    [No Abstract]   [Full Text] [Related]  

  • 2. Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination.
    Duffy PE
    Expert Rev Vaccines; 2021 Feb; 20(2):185-198. PubMed ID: 33478283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
    Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T
    Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Responses to Gametocyte Antigens in a Malaria Endemic Population-The African
    Muthui MK; Kamau A; Bousema T; Blagborough AM; Bejon P; Kapulu MC
    Front Immunol; 2019; 10():2480. PubMed ID: 31695697
    [No Abstract]   [Full Text] [Related]  

  • 5. A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes.
    Coelho CH; Tang WK; Burkhardt M; Galson JD; Muratova O; Salinas ND; Alves E Silva TL; Reiter K; MacDonald NJ; Nguyen V; Herrera R; Shimp R; Narum DL; Byrne-Steele M; Pan W; Hou X; Brown B; Eisenhower M; Han J; Jenkins BJ; Doritchamou JYA; Smelkinson MG; Vega-Rodríguez J; Trück J; Taylor JJ; Sagara I; Healy SA; Renn JP; Tolia NH; Duffy PE
    Nat Commun; 2021 Mar; 12(1):1750. PubMed ID: 33741942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.
    Kapulu MC; Da DF; Miura K; Li Y; Blagborough AM; Churcher TS; Nikolaeva D; Williams AR; Goodman AL; Sangare I; Turner AV; Cottingham MG; Nicosia A; Straschil U; Tsuboi T; Gilbert SC; Long CA; Sinden RE; Draper SJ; Hill AV; Cohuet A; Biswas S
    Sci Rep; 2015 Jun; 5():11193. PubMed ID: 26063320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Cao Y; Hayashi CTH; Araujo MDS; Tripathi AK; Andrade AO; Medeiros JF; Vinetz J; Kumar N
    Vaccine; 2024 Aug; 42(21):126140. PubMed ID: 39033079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending the range of Plasmodium falciparum transmission blocking antibodies.
    Simons LM; Ferrer P; Gombakomba N; Underwood K; Herrera R; Narum DL; Canepa G; Acquah F; Amoah L; Duffy PE; Barillas-Mury C; Long C; Lee SM; Locke E; Miura K; Williamson KC
    Vaccine; 2023 May; 41(21):3367-3379. PubMed ID: 37100721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
    Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
    Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
    MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL
    J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
    McGuire KA; Miura K; Wiethoff CM; Williamson KC
    Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of two lead malaria transmission blocking vaccine candidate antibodies in natural parasite-vector combinations.
    Bompard A; Da DF; Yerbanga RS; Biswas S; Kapulu M; Bousema T; Lefèvre T; Cohuet A; Churcher TS
    Sci Rep; 2017 Jul; 7(1):6766. PubMed ID: 28754921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of domains within Pfs230 that elicit transmission blocking antibody responses.
    Tachibana M; Miura K; Takashima E; Morita M; Nagaoka H; Zhou L; Long CA; Richter King C; Torii M; Tsuboi T; Ishino T
    Vaccine; 2019 Mar; 37(13):1799-1806. PubMed ID: 30824357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Characterization and Comparison of
    Nikolaeva D; Illingworth JJ; Miura K; Alanine DGW; Brian IJ; Li Y; Fyfe AJ; Da DF; Cohuet A; Long CA; Draper SJ; Biswas S
    Mol Cell Proteomics; 2020 Jan; 19(1):155-166. PubMed ID: 29089373
    [No Abstract]   [Full Text] [Related]  

  • 17. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
    Mlambo G; Maciel J; Kumar N
    Infect Immun; 2008 May; 76(5):2018-24. PubMed ID: 18316385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum.
    Ciubotariu II; Broyles BK; Xie S; Thimmapuram J; Mwenda MC; Mambwe B; Mulube C; Matoba J; Schue JL; Moss WJ; Bridges DJ; He Q; Carpi G
    EBioMedicine; 2024 Aug; 106():105227. PubMed ID: 39018754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
    Theisen M; Jore MM; Sauerwein R
    Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.